Navigation Links
Efforts to develop new drugs that hopefully will never be used
Date:6/27/2012

Concerns about terrorist attacks, the prospect of a rogue nation using nuclear weapons and the Fukushima power plant accident in Japan are fostering efforts to develop a new family of drugs that everyone hopes will never be used, according to an article in the current edition of Chemical & Engineering News (C&EN), the weekly newsmagazine of the American Chemical Society, the world's largest scientific society.

Ann M. Thayer, C&EN senior correspondent, explains that the federal government has launched programs to develop medical countermeasures against nuclear threats. Radiation releases can happen under various circumstances, including failure of safety systems at commercial nuclear power plants and terrorist attacks. The article describes programs run by the U.S. Food & Drug Administration (FDA), the U.S. Department of Health and Human Services and the National Institutes of Health that support several small companies as they try to develop drugs to treat acute radiation syndrome (ARS).

The article discusses the companies' approaches. Some seek to adapt existing drugs, including treatments for the side effects of radiation therapy for cancer. Thayer notes that because these drugs are already approved by the FDA, stockpiling them would be easier. Others are looking for new compounds that can treat the symptoms of ARS or remove radioactive particles from the body.


'/>"/>

Contact: Michael Bernstein
m_bernstein@acs.org
202-872-6042
American Chemical Society
Source:Eurekalert

Page: 1

Related biology news :

1. UCSD researchers: Where international climate policy has failed, grassroots efforts can succeed
2. Report details efforts to improve, advance indoor microbial sampling
3. Diabetes Research Institute develops oxygen-generating biomaterial
4. Artificial womb unlocks secrets of early embryo development
5. REST is crucial for the timing of brain development
6. Embryonic development protein active in cancer growth
7. Stanford scientists develop gene therapy approach to grow blood vessels in ischemic limbs
8. Mini-CT scanner developed as a teaching tool
9. Genetic research develops tools for studying diseases, improving regenerative treatment
10. Oceanographers develop method for measuring the pace of life in deep sediments
11. Scientists win $2 million to study new pathway in development and maintenance of lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/3/2017)... VEGAS , Jan. 3, 2017 Onitor, ... the introduction of Onitor Track, an innovative biometric data-driven ... men, showcasing this month at the 2017 Consumer Electronics ... In the U.S., the World Health ... more than two-thirds of adults who are overweight or ...
(Date:12/20/2016)... Dec, 20, 2016   Valencell , the ... and STMicroelectronics (NYSE: STM), a global semiconductor ... applications, announced today the launch of a new, ... wearables that includes ST,s compact SensorTile ... biometric sensor system. Together, SensorTile and Benchmark ...
(Date:12/16/2016)... YORK , Dec. 16, 2016 The global wearable ... USD 12.14 billion by 2021 from USD 5.31 billion in 2016, ... ... is mainly driven by technological advancements in medical devices, launch of ... rising preference for wireless connectivity among healthcare providers, and increasing focus ...
Breaking Biology News(10 mins):
(Date:1/16/2017)... LOUISVILLE, Ky. , Jan. 16, 2017  Eurofins ... service, which will allow more customers to receive their ... price premium or compromise in quality found with other ... the United States at no additional ... variety of routine genetic studies, including DNA sequencing, genotyping, ...
(Date:1/13/2017)... Research and Markets has announced the addition of the "Global Biopolymers ... ... of 16.83% during the period 2017-2021. The report covers ... for 2017-2021. To calculate the market size, the report considers the revenue ... includes a a discussion of the key vendors operating in this market. ...
(Date:1/12/2017)... ... January 12, 2017 , ... ... A SUCCESS , VTI, Vertebral Technologies, Inc., announces the successful outcome of ... device. Since September 2016, VTI (Vertebral Technologies, Inc.) has partnered with Mexico-based ...
(Date:1/12/2017)... , ... January 12, 2017 , ... ... targeted treatments, 26-year-old Lisa Rosendahl’s doctors gave her only a few months to ... new drug combination that has stabilized Rosendahl’s disease and increased both the quantity ...
Breaking Biology Technology: